patients with stable coronary artery disease
Conditions
Brief summary
The primary outcome will be plasma high-sensitivity C-reactive protein (hsCRP) concentration. HsCRP will be measured at inclusion (basal value before vaccination) and at the end of the study (1 month). The variation in the HsCRP value will be compared between the group of subjects vaccinated just after inclusion (intervention group, “immediate” vaccination) and the group of subjects vaccinated at 1 month (control group, “follow-up” vaccination).
Detailed description
1) Plasma concentration of inflammatory markers of CVD risk: interleukin (IL)-6, IL-1b, and tumor necrosis factor-α), NT-pro-BNP, fibrinogen., 2) Plasma concentration of arterial vulnerability markers: Apolipoprotein B, lipoprotein(a), LDL., 3) Characterization of circulating immune cells: - Expression level of genes involved in the T cell response (CD3, CD4, CD8) and in its Th1 (Tbet), Th2 (GATA3), Th17 (RORγ), Treg (FOXP3) orientation analyzed by an RT- technique qPCR. - Percentage of B lymphocytes (CD45+CD19+), T lymphocytes (CD45+CD3+), and monocytes (CD45+CD14+CD11c+) among PBMCs determined by flow cytometry., 4) Antibody titer at 1 month measured by the hemagglutination inhibition titer for each strain of the vaccine.
Interventions
Sponsors
Centre Hospitalier Regional Universitaire De Tours
Eligibility
Sex/Gender
All
Age
65 Years to No maximum
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The primary outcome will be plasma high-sensitivity C-reactive protein (hsCRP) concentration. HsCRP will be measured at inclusion (basal value before vaccination) and at the end of the study (1 month). The variation in the HsCRP value will be compared between the group of subjects vaccinated just after inclusion (intervention group, “immediate” vaccination) and the group of subjects vaccinated at 1 month (control group, “follow-up” vaccination). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1) Plasma concentration of inflammatory markers of CVD risk: interleukin (IL)-6, IL-1b, and tumor necrosis factor-α), NT-pro-BNP, fibrinogen., 2) Plasma concentration of arterial vulnerability markers: Apolipoprotein B, lipoprotein(a), LDL., 3) Characterization of circulating immune cells: - Expression level of genes involved in the T cell response (CD3, CD4, CD8) and in its Th1 (Tbet), Th2 (GATA3), Th17 (RORγ), Treg (FOXP3) orientation analyzed by an RT- technique qPCR. - Percentage of B lymphocytes (CD45+CD19+), T lymphocytes (CD45+CD3+), and monocytes (CD45+CD14+CD11c+) among PBMCs determined by flow cytometry., 4) Antibody titer at 1 month measured by the hemagglutination inhibition titer for each strain of the vaccine. | — |
Countries
France
Outcome results
None listed